Treatment Of Symptomatic Asthma In Children
Condition: Asthma
MeSH terms: Asthma
Intervention: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; fluticasone propionate 2 x 100 mcg
Intervention description: comparator; comparator
Intervention MeSH terms: Fluticasone; Xhance; Salmeterol Xinafoate
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 176.0
Sex: All
Minimum age: 6 Years
Maximum age: 12 Years
Healthy volunteers: No
Keywords: salmeterol/fluticasone combination; Asthma; bronchial hyperresponsiveness; Children; symptom control

Summary:

      This study is being conducted to investigate whether in childhood salmeterol/ fluticasone
      propionate 50/100 bd delivered via the Diskus® inhaler and fluticasone propionate 200 mcg bd
      delivered via the Diskus® inhaler are non- inferior in terms of symptom control. Additionally
      we aim to show that salmeterol/ fluticasone propionate 50/100 bd is at least as good in terms
      of lung function improvement and bronchial hyperreactivity and enables a steroid-sparing
      management of asthma in children.
    

Eligibility criteria:

        Inclusion criteria:

          -  Male or female subjects aged 6-12 years (inclusive)

          -  A female is eligible to enter and participate in the study if she is:

        of non-child-bearing potential; OR of child-bearing potential, but not lactating and
        pregnant. She declares that it is not probable that she will become pregnant during the
        study (a pregnancy test can be performed at the investigators discretion)

          -  Subjects with a documented history of asthma for at least 6 months

          -  Subjects with a documented history of BHR within 12 months prior to inclusion or BHR
             on visit 1 (PD20 methacholine < 150 mcg or an equivalence for histamine)

          -  Subjects who have received BDP, budesonide up to 100-200 mcg bd or fluticasone
             propionate at a dose of up to 125 mcg bd for at least 4 weeks before the start of the
             run-in period.

          -  Subjects who are able to use a electronic peakflow /FEV1 meter (PIKO-1)

          -  Subjects who have a normal length SD score between -2SD and +2SD

          -  Subjects who are able to use a Diskus inhaler

          -  Subjects who are able to perform reproducible lung function tests at visit 1
             (variation FEV1 < 5% between the two best measurements)

          -  Subjects and their guardians, who have given written informed consent to participate
             in the study

          -  Subjects or their parent/ guardian who are able to understand and complete a DRC. The
             DRC may be completed by a parent/guardian if the subject is unable to do this him/
             herself

          -  Subjects able to use Ventolin on an 'as required for symptoms' basis

        Exclusion criteria:

          -  Subjects who have been hospitalised for their asthma within 4 weeks of visit 1

          -  Subjects who had an acute upper respiratory tract infection within 2 weeks or a lower
             respiratory tract infection within 4 weeks prior to visit 1

          -  Subjects who received oral, parental or depot corticosteroids within 4 weeks prior to
             visit 1

          -  Subjects who have a known respiratory disorder other than asthma and/or
             systemic/thoracic abnormalities which influence normal lung function

          -  Subjects with a disorder that affects growth (e.g. Turner's syndrome)

          -  Subjects who have received any investigational drugs within 4 weeks of visit 1

          -  Subjects with a known or suspected hypersensitivity to inhaled steroids, β2-agonists
             or lactose

          -  Subjects who use any medication that significantly inhibit the cytochrome P450
             subfamily enzyme CYP3A4, including ritonavir and ketoconazole

          -  Subjects who concurrently participate in another clinical study

          -  Subjects who have previously been randomised in this trial